

James Brett Case

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1115987/publications.pdf>

Version: 2024-02-01

45
papers

11,571
citations

117453

34
h-index

233125

45
g-index

69
all docs

69
docs citations

69
times ranked

16006
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. <i>Nature</i> , 2020, 583, 290-295. | 13.7 | 1,695 |
| 2 | Potently neutralizing and protective human antibodies against SARS-CoV-2. <i>Nature</i> , 2020, 584, 443-449. | 13.7 | 956 |
| 3 | Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726. | 15.2 | 838 |
| 4 | SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. <i>Nature</i> , 2021, 596, 109-113. | 13.7 | 586 |
| 5 | Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. <i>Nature Immunology</i> , 2020, 21, 1506-1516. | 7.0 | 563 |
| 6 | Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. <i>Science</i> , 2020, 370, 950-957. | 6.0 | 504 |
| 7 | A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. <i>Cell</i> , 2020, 182, 744-753.e4. | 13.5 | 486 |
| 8 | SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. <i>Nature</i> , 2022, 603, 687-692. | 13.7 | 475 |
| 9 | De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. <i>Science</i> , 2020, 370, 426-431. | 6.0 | 464 |
| 10 | Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. <i>Nature Medicine</i> , 2020, 26, 1422-1427. | 15.2 | 450 |
| 11 | A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. <i>Cell</i> , 2020, 183, 169-184.e13. | 13.5 | 446 |
| 12 | Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 28, 475-485.e5. | 5.1 | 380 |
| 13 | The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , 2021, 184, 2183-2200.e22. | 13.5 | 331 |
| 14 | Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. <i>Cell</i> , 2021, 184, 1804-1820.e16. | 13.5 | 297 |
| 15 | Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244. | 5.9 | 237 |
| 16 | In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108. | 13.7 | 222 |
| 17 | Growth, detection, quantification, and inactivation of SARS-CoV-2. <i>Virology</i> , 2020, 548, 39-48. | 1.1 | 209 |
| 18 | Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32105-32113. | 3.3 | 192 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 19 | A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Journal of Immunology</i> , 2020, 205, 915-922. | 0.4 | 186 |
| 20 | Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. <i>Cell Host and Microbe</i> , 2020, 28, 465-474.e4. | 5.1 | 156 |
| 21 | Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 20803-20813. | 3.3 | 154 |
| 22 | A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters. <i>Cell Reports</i> , 2021, 36, 109400. | 2.9 | 119 |
| 23 | Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays. <i>Clinical Chemistry</i> , 2020, 66, 1538-1547. | 1.5 | 112 |
| 24 | A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. <i>Cell Reports Medicine</i> , 2021, 2, 100230. | 3.3 | 99 |
| 25 | SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. <i>Cell Reports</i> , 2021, 37, 110143. | 2.9 | 94 |
| 26 | Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 93 |
| 27 | A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. <i>Immunity</i> , 2021, 54, 2399-2416.e6. | 6.6 | 79 |
| 28 | LDLRAD3 is a receptor for Venezuelan equine encephalitis virus. <i>Nature</i> , 2020, 588, 308-314. | 13.7 | 78 |
| 29 | A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, . | 5.8 | 73 |
| 30 | Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. <i>Cell</i> , 2022, 185, 1572-1587.e11. | 13.5 | 71 |
| 31 | Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. <i>Science Translational Medicine</i> , 2022, 14, eabn1252. | 5.8 | 68 |
| 32 | SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice. <i>Journal of Virology</i> , 2022, 96, JV10151121. | 1.5 | 58 |
| 33 | A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021, 54, 2159-2166.e6. | 6.6 | 52 |
| 34 | The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. <i>Cell Host and Microbe</i> , 2022, 30, 53-68.e12. | 5.1 | 52 |
| 35 | On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85. | 1.1 | 38 |
| 36 | Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. <i>Cell Host and Microbe</i> , 2021, 29, 1151-1161.e5. | 5.1 | 36 |

| # | ARTICLE | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. <i>Journal of Molecular Biology</i> , 2021, 433, 167177. | 2.0 | 31 |
| 38 | The Translational Landscape of SARS-CoV-2-infected Cells Reveals Suppression of Innate Immune Genes. <i>MBio</i> , 2022, 13, . | 1.8 | 21 |
| 39 | Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 2020, , 3606354. | 0.4 | 16 |
| 40 | Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. <i>Cell Reports</i> , 2022, 38, 110561. | 2.9 | 16 |
| 41 | Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. <i>Cell Reports</i> , 2021, 37, 109881. | 2.9 | 14 |
| 42 | JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis. <i>MBio</i> , 2022, 13, e0337721. | 1.8 | 14 |
| 43 | An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 3.9 | 14 |
| 44 | Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. <i>MBio</i> , 2022, 13, e0323821. | 1.8 | 11 |
| 45 | Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies. <i>Cell Reports</i> , 2022, 39, 110905. | 2.9 | 5 |